Table 2 Five studies assessing the safety of ivermectin during pregnancy compared with community based controls
Reference | Country | Number of pregnant women | Number inadvertently treated | In the first trimester | Pregnancy outcome | Child mortality | Child development |
|---|---|---|---|---|---|---|---|
Pacque et al. [81] | Liberia | 939 | 200 | 171 (85%) | No difference with controls | No difference with controls | No difference with controls (follow-up 2Â years) |
Doumbo et al. [102] | Mali | 461 | 82 | Not stated | Data not readily assessable | ||
Chippaux et al. [103] | Cameroon | 511 | 110 | (93) 85% | No difference with controls | No difference with controls | No difference with controls (follow-up 1Â year) |
Gyapong et al. [104] | Ghana | 343 | 50 | (50) 100% | No difference with controls | No difference with controls | No difference with controls (follow-up not stated) |
Ndyomugyenyi et al. [105] | Uganda | 834 | 397a | All in 2nd trimester | No difference with controls | No difference with controls | Not included |